請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65538
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李財坤 | |
dc.contributor.author | Hsuan-Hsuan Chang | en |
dc.contributor.author | 張軒瑄 | zh_TW |
dc.date.accessioned | 2021-06-16T23:49:12Z | - |
dc.date.available | 2020-03-02 | |
dc.date.copyright | 2020-03-02 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-02-17 | |
dc.identifier.citation | 1. Ashley, E. (2015). The Precision Medicine Initiative. JAMA, 313(21), 2119. doi: 10.1001/jama.2015.3595
2. Bouvier, N., & Palese, P. (2008). The biology of influenza viruses. Vaccine, 26, D49-D53. doi: 10.1016/j.vaccine.2008.07.039 3. DailyMed - XOFLUZA- baloxavir marboxil tablet, film coated. (2019). Retrieved 10 November 2019, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7 4. Demetrius, L., & Driver, J. (2013). Alzheimer’s as a metabolic disease. Biogerontology, 14(6), 641-649. doi: 10.1007/s10522-013-9479-7 5. Demicheli, V., Jefferson, T., Al-Ansary, L., Ferroni, E., Rivetti, A., & Di Pietrantonj, C. (2014). Vaccines for preventing influenza in healthy adults. Cochrane Database Of Systematic Reviews. doi: 10.1002/14651858.cd001269.pub5 6. Eccles, R. (2005). Understanding the symptoms of the common cold and influenza. The Lancet Infectious Diseases, 5(11), 718-725. doi: 10.1016/s1473-3099(05)70270-x 7. Egan, M., Kost, J., Voss, T., Mukai, Y., Aisen, P., & Cummings, J. et al. (2019). Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease. New England Journal Of Medicine, 380(15), 1408-1420. doi: 10.1056/nejmoa1812840 8. Elazezy, M., & Joosse, S. (2018). Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Computational And Structural Biotechnology Journal, 16, 370-378. doi: 10.1016/j.csbj.2018.10.002 9. Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019). Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease. New England Journal Of Medicine, 380(15), 1483-1485. doi: 10.1056/nejmc1813435 10. Holtzman, N. (1999). Are Genetic Tests Adequately Regulated?. Science, 286(5439), 409-409. doi: 10.1126/science.286.5439.409 11. HUMAN PRESCRIPTION DRUG LABEL - XOFLUZA- baloxavir marboxil tablet, film coated. (2019). Retrieved 18 November 2019, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7 12. Hwang, S., & Kim, J. (2020). Fluoxetine Induces Apoptotic and Oxidative Neuronal Death Associated with The Influx of Copper Ions in Cultured Neuronal Cells. Chonnam Medical Journal, 56(1), 20. doi: 10.4068/cmj.2020.56.1.20 13. Khagi, Y., Goodman, A., Daniels, G., Patel, S., Sacco, A., & Randall, J. et al. (2017). Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy. Clinical Cancer Research, 23(19), 5729-5736. doi: 10.1158/1078-0432.ccr-17-1439 14. Kidd, B., Hoffman, G., Zimmerman, N., Li, L., Morgan, J., & Glowe, P. et al. (2016). Evaluation of direct-to-consumer low-volume lab tests in healthy adults. Journal Of Clinical Investigation, 126(5), 1734-1744. doi: 10.1172/jci86318 15. Kidd, B., Hoffman, G., Zimmerman, N., Li, L., Morgan, J., & Glowe, P. et al. (2016). Evaluation of direct-to-consumer low-volume lab tests in healthy adults. Journal Of Clinical Investigation, 126(5), 1734-1744. doi: 10.1172/jci86318 16. Koonin, E., & Wolf, Y. (2010). Constraints and plasticity in genome and molecular-phenome evolution. Nature Reviews Genetics, 11(7), 487-498. doi: 10.1038/nrg2810 17. Liquid Biopsies Using Plasma Exosomal Nucleic Acids. (2019). Oncoscience, 296. doi: 10.18632/oncoscience.478 18. Liquid-biopsies success highlights power of combining basic and clinical research. (2017). Nature, 544(7651), 393-393. doi: 10.1038/544393a 19. ltd, R. (2019). Healthcare Contract Manufacturing Outsourcing (CMO) Market - Forecasts from 2016 to 2021. Retrieved 17 November 2019, from https://www.researchandmarkets.com/research/z4vndz/healthcare 20. ltd, R. (2019). Healthcare Contract Manufacturing Outsourcing (CMO) Market - Forecasts from 2016 to 2021. Retrieved 17 November 2019, from https://www.researchandmarkets.com/research/z4vndz/healthcare 21. Printz, C. (2018). Liquid biopsies offer promise and challenges. Cancer, 124(11), 2269-2270. doi: 10.1002/cncr.31547 22. Razvi, E. (2014). Circulating Biomarkers for Liquid Biopsies. Clinical Omics, 1(3), 24-24. doi: 10.1089/clinomi.01.03.08 23. Seyfried, T., & Shelton, L. (2010). Cancer as a metabolic disease. Nutrition & Metabolism, 7(1), 7. doi: 10.1186/1743-7075-7-7 24. Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., & Wang, G. et al. (2018). Effect of exosomal miRNA on cancer biology and clinical applications. Molecular Cancer, 17(1). doi: 10.1186/s12943-018-0897-7 25. Wishart, D., Knox, C., Guo, A., Eisner, R., Young, N., & Gautam, B. et al. (2009). HMDB: a knowledgebase for the human metabolome. Nucleic Acids Research, 37(Database), D603-D610. doi: 10.1093/nar/gkn810 26. Wishart, D., Tzur, D., Knox, C., Eisner, R., Guo, A., & Young, N. et al. (2007). HMDB: the Human Metabolome Database. Nucleic Acids Research, 35(Database), D521-D526. doi: 10.1093/nar/gkl923 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65538 | - |
dc.description.abstract | 醫療體制的均衡發展為長期存在的問題,政府、醫院、製藥公司、醫學檢驗、保險、生技公司、資本、病患、倫理等,存在如何維持平衡的取捨難題,提出新的商業模式來做為解決方案成為各方努力之機會所在。探討在不同視野下醫療生技產業衡量跨界資源與產業生態平衡的思路。期望在國家制定產業政策時有更前瞻的思維,進而有效提升國際化實質競爭能力、建立醫療生技企業更全面的綜合發展策略,資本市場在醫療生技產業的運作更加全面宏觀上做出貢獻。 | zh_TW |
dc.description.abstract | The balanced development of the medical system is a long-standing issue. Specially, challenges have occurred in maintaining a balance among factors such as the government, hospitals, pharmaceutical companies, medical laboratories, insurance companies, biotechnology, capital, patients, and ethics. Therefore, a new business model might be of interest to relevant parties who wish to resolve such challenges. This study, from various perspectives, discussed the medicine and biotechnology industry’s mindset in gaining interdisciplinary resources and obtaining a balance in the industrial ecosystem. The study’s findings may contribute to building a pioneering mindset of the country in industrial policy formulation, which could effectively improve its international competitiveness; to establishing comprehensive developmental strategies in medical and biotechnological companies; and to realizing the medicine and biotechnology industry’s comprehensive operations at the macro level in capital markets.
Keyword:Medicine and Biotechnology Management、Liquid Biopsy、In Vitro Diagnostic Device(IVD)、Precision Medicine、Theranos | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:49:12Z (GMT). No. of bitstreams: 1 ntu-109-P06e43021-1.pdf: 6658991 bytes, checksum: b4c6ffd95c419a6331938174521f11ef (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 誌謝 - 2 -
中文摘要 - 3 - ABSTRACT - 4 - 目錄 - 5 - 圖目錄 - 8 - 表目錄 - 9 - 第一章 產業發展 - 10 - 1.1 醫療生技產業供需路徑與關係 - 11 - 1.1.1 疾病醫療 - 12 - 1.1.2 產品研發 - 12 - 1.1.3 商品銷售 - 13 - 1.1.4 資本運作 - 14 - 1.2 醫療生技產業供需機制衍生爭點 - 15 - 1.2.1 疾病醫療 - 15 - 1.2.1.1 供需議價能力 - 15 - 1.2.1.2 資訊不對稱落差 - 15 - 1.2.1.3 前期疾病干預 - 15 - 1.2.2 資本運作 - 18 - 1.2.2.1 專業門檻考驗查核能力 - 18 - 1.2.2.2 資本套利與排擠效應 - 19 - 1.2.2.3 法規遊說與政治干預 - 19 - 1.2.3 研發銷售 - 19 - 1.2.3.1 環節銜接 - 19 - 1.2.3.2 機轉改變 - 21 - 1.2.4 訂價機制與利潤 - 22 - 1.2.4.1 需求訂價 - 23 - 1.2.4.2 藥物行銷 - 24 - 1.2.4.3學名藥競爭 - 24 - 1.3 精準醫療與精準診斷 - 26 - 1.3.1 朝向疾病管理發展 - 26 - 1.3.2 液態檢體應用價值 - 26 - 1.3.3 分析方法與判讀 - 26 - 1.3.4 精準診斷臨床落實 - 28 - 第二章 企業角度 - 29 - 2.1 整體市場概況 - 29 - 2.2.1 聯合寡佔 - 30 - 2.2.2 市場增長策略 - 32 - 2.2 新創公司-Theranos - 33 - 2.2.1 改變醫療模式之商業模式創新 - 33 - 2.2.1.1 提前檢測介入 - 34 - 2.2.1.2 縮短檢測時間 - 34 - 2.2.1.3 導向價格透明以低價競爭 - 34 - 2.2.1.4 立法遊說去醫化 - 35 - 2.2.1.5 檢測消費商品化 - 35 - 2.2.2 資金磁吸公關綜效 - 35 - 2.2.3 技術研發侷限 - 37 - 2.2.4 業務拓展 - 39 - 2.2.5 退場策略失靈 - 39 - 2.2.6 證卷詐欺與司法調查 - 39 - 2.3 台灣公司 - 42 - 2.3.1 台灣生技公司概況 - 42 - 2.3.2 產業擴張策略 - 43 - 2.3.3 產業競爭分析 - 43 - 2.3.4 資金來源與發展路徑 - 45 - 2.3.5 策略思維的困境 - 45 - 2.3.5.1本夢比與本益比考驗 - 45 - 2.3.5.2一條龍整合之價值弱化 - 46 - 2.3.6 科學家思維與臨床醫學應用斷軌- 47 - 2.3.7 專業生技醫療管理人材缺乏 - 47 - 第三章 資本投資業角度 - 48 - 3.1 公開發行市場 - 48 - 3.2 權威投資效應 - 52 - 3.3 鑑價與估值 - 53 - 3.4 公關效應與股價操作 - 54 - 3.5 科學研究成果陷阱 - 56 - 3.6 專利保護與技術揭露風險 - 57 - 3.7 投資後管理與退場機制 - 60 - 第四章 政府監管角度 - 61 - 4.1 政策扶植下的產業競爭 - 61 - 4.2 單向抑制藥價 - 63 - 第五章 結論 - 64 - 5.1 趨勢與困境 - 64 - 5.2 放鬆資金管制活絡市場 - 64 - 5.3 加強臨床實驗檢測健全產業發展- 65 - 5.4 深化醫療體制改革 - 65 - 參考文獻 - 66 - 附錄1.體外診斷宣稱標誌與認證比較- 69 - 附錄2. House Bill 2645 - 70 - 附錄3 使用微量血診斷技術2017市場情況- 74 - 附錄4. Holmes and Balwani Indictment- 77 - 附錄5. Discussion Paper on Laboratory Developed Tests (LDTs) from FDA- 93 - 圖目錄 圖1 醫療產業供需機制現況 - 11 - 圖2 A、B型流感病毒作用機轉與治療干預- 17 - 圖3 產品研發過程 - 20 - 圖4 藥物價格制訂影響與關係- 23 - 圖5 精準醫療疾病管理應用 - 26 - 圖6 液態生物檢體檢測分析方法- 27 - 圖7 全球體外診斷市場占有率分布- 29 - 圖8 改變醫療模式之商業模式創新- 33 - 圖9 血液中生物標記物理範圍與含量- 37 - 圖10 .Theranos、Quest、LabCorp檢測結果比對分析- 38 - 圖11 台灣生技公司發展路徑- 45 - 圖12 醫療生技產業與傳統製造業股價與盈利差異- 49 - 圖13 主要資本市場生技類股市值比較- 50 - 圖14 各類型資本投資業者投資進場與退場時機- 52 - 圖15 台灣浩鼎事件與股價關係圖- 55 - 圖16 .Sirtuins(STAC抗衰老酶)型態與專利佈局 - 56 - 圖17 研發流程與風險價值曲線- 57 - 圖18 政策扶植產業競爭模型- 61 - 表目錄 表1 液態檢體分析判讀比較- 28 - 表2 .Theranos司法調查結果與影響- 40 - 表3 台灣液態檢體診斷領域公開發行生技公司之核心競爭力- 42 - 表4 醫療生技產業與傳統製造業特性差異- 43 - 表5 台灣生技公司五力分析與產業擴張策略- 44 - 表6 醫療生技產業與傳統製造業投資獲利比較- 48 - 表7 台灣生技公司IPO市場遷移- 50 - 表8 資本市場主要生技類股市值規模- 51 - 表9 專利種類- 58 - 表10營業秘密與專利比較分析- 59 - 表11台灣研發各階段政府補助措施與計畫- 62 - | |
dc.language.iso | zh-TW | |
dc.title | 液態檢體檢測於醫療生技產業商業模式探討 | zh_TW |
dc.title | Business Model of Liquid Biopsies Testing
in Medical Biotechnology Industry | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 何家安,沈湯龍 | |
dc.subject.keyword | 醫療生技管理,液態檢體,體外診斷,精準醫療,Theranos, | zh_TW |
dc.subject.keyword | Medicine and Biotechnology Management,Liquid Biopsy,In Vitro Diagnostic Device(IVD),Precision Medicine,Theranos, | en |
dc.relation.page | 105 | |
dc.identifier.doi | 10.6342/NTU201904456 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-02-18 | |
dc.contributor.author-college | 進修推廣學院 | zh_TW |
dc.contributor.author-dept | 生物科技管理碩士在職學位學程 | zh_TW |
顯示於系所單位: | 生物科技管理碩士在職學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-109-1.pdf 目前未授權公開取用 | 6.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。